CD44s and CD44v6 Expression in Head and Neck EpitheliaReport as inadecuate

CD44s and CD44v6 Expression in Head and Neck Epithelia - Download this document for free, or read online. Document in PDF available to download.


CD44 splice variants are long-known as being associated with cell transformation. Recently, the standard form of CD44 CD44s was shown to be part of the signature of cancer stem cells CSCs in colon, breast, and in head and neck squamous cell carcinomas HNSCC. This is somewhat in contradiction to previous reports on the expression of CD44s in HNSCC. The aim of the present study was to clarify the actual pattern of CD44 expression in head and neck epithelia.


Expression of CD44s and CD44v6 was analysed by immunohistochemistry with specific antibodies in primary head and neck tissues. Scoring of all specimens followed a two-parameters system, which implemented percentages of positive cells and staining intensities from − to +++ score = %×intensity; resulting max. score 300. In addition, cell surface expression of CD44s and CD44v6 was assessed in lymphocytes and HNSCC.


In normal epithelia CD44s and CD44v6 were expressed in 60–95% and 50–80% of cells and yielded mean scores with a standard error of a mean SEM of 249.5±14.5 and 198±11.13, respectively. In oral leukoplakia and in moderately differentiated carcinomas CD44s and CD44v6 levels were slightly increased 278.9±7.16 and 242±11.7; 291.8±5.88 and 287.3±6.88. Carcinomas in situ displayed unchanged levels of both proteins whereas poorly differentiated carcinomas consistently expressed diminished CD44s and CD44v6 levels. Lymphocytes and HNSCC lines strongly expressed CD44s but not CD44v6.


CD44s and CD44v6 expression does not distinguish normal from benign or malignant epithelia of the head and neck. CD44s and CD44v6 were abundantly present in the great majority of cells in head and neck tissues, including carcinomas. Hence, the value of CD44s as a marker for the definition of a small subset of cells i.e. less than 10% representing head and neck cancer stem cells may need revision.

Author: Brigitte Mack, Olivier Gires



Related documents